NYSEAMERICAN:NNVCNanoViricides Stock Price, Forecast & News

NanoViricides Inc (NYSEAMERICAN:NNVC) posted its quarterly earnings data on Tuesday, February, 19th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.08. View NanoViricides' earnings history.

NanoViricides shares reverse split before market open on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split.

News articles about NNVC stock have been trending somewhat negative this week, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. NanoViricides earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutNanoViricides.

NanoViricides saw a decline in short interest in May. As of May 15th, there was short interest totaling 327,000 shares, a decline of 5.8% from the April 30th total of 347,000 shares. Based on an average daily trading volume, of 1,690,000 shares, the short-interest ratio is presently 0.2 days. Approximately 5.2% of the shares of the company are sold short. View NanoViricides' Current Options Chain.

Some companies that are related to NanoViricides include BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Trilogy International Partners (TRL), Recce Pharmaceuticals (RCE), Futura Medical (FUM), Vita Life Sciences (VLS), Pharmaxis (PXS), Sareum (SAR), Avivagen (VIV), Antisense Therapeutics (ANP), China Pharma (CPHI), Patrys (PAB), Cathay International (CTI) and N4 Pharma (N4P). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Micron Technology (MU), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Domino's Pizza (DPZ), AbbVie (ABBV), Novavax (NVAX), Vaxart (VXRT) and NVIDIA (NVDA).

NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."

NanoViricides' stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (0.63%), Harvest Investment Services LLC (0.26%), Wedbush Securities Inc. (0.14%) and UBS Group AG (0.06%). View institutional ownership trends for NanoViricides.

NNVC stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Harvest Investment Services LLC, Wedbush Securities Inc., and UBS Group AG. View insider buying and selling activity for NanoViricides.

Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NNVC stock can currently be purchased for approximately $7.45.

NanoViricides has a market capitalization of $55.19 million. NanoViricides employs 7 workers across the globe.

The official website for NanoViricides is www.nanoviricides.com.

NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at +1-203-9376137.